[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 28, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 987100, "exercisedValue": 0, "unexercisedValue": 13998124}, {"maxAge": 1, "name": "Mr. Gregory S. Zante", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655000, "exercisedValue": 0, "unexercisedValue": 59203}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 58, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 670000, "exercisedValue": 0, "unexercisedValue": 2005070}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 58, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Senior Vice President of Pharmaceutical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 56.2, "open": 57.25, "dayLow": 57.0, "dayHigh": 58.81, "regularMarketPreviousClose": 56.2, "regularMarketOpen": 57.25, "regularMarketDayLow": 57.0, "regularMarketDayHigh": 58.81, "beta": 1.024, "forwardPE": -38.039215, "volume": 2186128, "regularMarketVolume": 2186128, "averageVolume": 3894803, "averageVolume10days": 2769260, "averageDailyVolume10Day": 2769260, "bid": 58.17, "ask": 58.29, "bidSize": 400, "askSize": 400, "marketCap": 6448327168, "fiftyTwoWeekLow": 8.28, "fiftyTwoWeekHigh": 99.41, "fiftyDayAverage": 54.244, "twoHundredDayAverage": 46.13415, "currency": "USD", "enterpriseValue": 5507175936, "floatShares": 104772211, "sharesOutstanding": 110796000, "sharesShort": 16862235, "sharesShortPriorMonth": 16825918, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.1522, "heldPercentInsiders": 0.05975, "heldPercentInstitutions": 0.76555, "shortRatio": 4.06, "shortPercentOfFloat": 0.2048, "impliedSharesOutstanding": 120068000, "bookValue": 8.312, "priceToBook": 7.001925, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -96745000, "trailingEps": -0.93, "forwardEps": -1.53, "pegRatio": -1.39, "52WeekChange": 3.115983, "SandP52WeekChange": 0.24822903, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VKTX", "underlyingSymbol": "VKTX", "shortName": "Viking Therapeutics, Inc.", "longName": "Viking Therapeutics, Inc.", "firstTradeDateEpochUtc": 1430227800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e658b393-1b8d-3e3b-b1d5-0d5bdf22cb43", "messageBoardId": "finmb_246791410", "gmtOffSetMilliseconds": -14400000, "currentPrice": 58.2, "targetHighPrice": 138.0, "targetLowPrice": 90.0, "targetMeanPrice": 113.55, "targetMedianPrice": 118.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 942262976, "totalCashPerShare": 8.504, "totalDebt": 1100000, "quickRatio": 37.551, "currentRatio": 37.689, "debtToEquity": 0.119, "returnOnAssets": -0.11565, "returnOnEquity": -0.14803, "freeCashflow": -39389376, "operatingCashflow": -71945000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-15"}]